Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

A higher sport-related reinjury risk does not mean inadequate rehabilitation: the methodological challenge of choosing the correct comparison group.

Shrier I, Zhao M, Piché A, Slavchev P, Steele RJ.

Br J Sports Med. 2017 Apr;51(8):630-635. doi: 10.1136/bjsports-2016-096922. Epub 2017 Feb 20. Review.

PMID:
28219942
2.

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling.

Lane D, Matte I, Laplante C, Garde-Granger P, Carignan A, Bessette P, Rancourt C, Piché A.

Mol Cancer. 2016 Sep 9;15(1):58. doi: 10.1186/s12943-016-0542-2.

3.

Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.

Matte I, Legault CM, Garde-Granger P, Laplante C, Bessette P, Rancourt C, Piché A.

Clin Exp Metastasis. 2016 Dec;33(8):839-852. Epub 2016 Sep 9.

PMID:
27612856
4.

Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors.

El-Far M, Kouassi P, Sylla M, Zhang Y, Fouda A, Fabre T, Goulet JP, van Grevenynghe J, Lee T, Singer J, Harris M, Baril JG, Trottier B, Ancuta P, Routy JP, Bernard N, Tremblay CL; Investigators of the Canadian HIV+ Slow Progressor Cohort.

Sci Rep. 2016 Mar 15;6:22902. doi: 10.1038/srep22902.

5.

The Molecular Taxonomy of Primary Prostate Cancer.

Cancer Genome Atlas Research Network.

Cell. 2015 Nov 5;163(4):1011-25. doi: 10.1016/j.cell.2015.10.025.

6.

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.

Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piché A.

BMC Cancer. 2015 Jul 1;15:492. doi: 10.1186/s12885-015-1511-7.

7.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

8.

MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling.

Giannakouros P, Comamala M, Matte I, Rancourt C, Piché A.

Am J Cancer Res. 2014 Dec 15;5(1):219-30. eCollection 2015.

9.

Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.

Matte I, Lane D, Laplante C, Garde-Granger P, Rancourt C, Piché A.

Int J Cancer. 2015 Jul 15;137(2):289-98. doi: 10.1002/ijc.29385. Epub 2014 Dec 18.

10.

Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail.

Giannakouros P, Matte I, Rancourt C, Piché A.

Int J Oncol. 2015 Jan;46(1):91-8. doi: 10.3892/ijo.2014.2707. Epub 2014 Oct 14.

PMID:
25338620
11.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

12.

Specimen quality evaluation in Canadian biobanks participating in the COEUR repository.

Le Page C, Köbel M, de Ladurantaye M, Rahimi K, Madore J, Babinszky S, Bachvarov DR, Bachvarova M, Beauchamp MC, Cass CE, Chadwick D, Colleen C, Damaraju S, Dufour J, Gotlieb WH, Kalloger SE, Portelance L, McAlpine JN, Matte I, Piché A, Shaw P, Roehrl MH, Vanderhyden BC, Watson PH, Huntsman DG, Provencher DM, Mes-Masson AM.

Biopreserv Biobank. 2013 Apr;11(2):83-93. doi: 10.1089/bio.2012.0044. Erratum in: Biopreserv Biobank. 2013 Aug;11(4):257. Roehrl, Michael H A [added].

PMID:
24845429
13.

Role of malignant ascites on human mesothelial cells and their gene expression profiles.

Matte I, Lane D, Bachvarov D, Rancourt C, Piché A.

BMC Cancer. 2014 Apr 24;14:288. doi: 10.1186/1471-2407-14-288.

14.

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.

Matte I, Lane D, Boivin M, Rancourt C, Piché A.

BMC Cancer. 2014 Apr 1;14:234. doi: 10.1186/1471-2407-14-234.

15.

The VACS index accurately predicts mortality and treatment response among multi-drug resistant HIV infected patients participating in the options in management with antiretrovirals (OPTIMA) study.

Brown ST, Tate JP, Kyriakides TC, Kirkwood KA, Holodniy M, Goulet JL, Angus BJ, Cameron DW, Justice AC; OPTIMA Team.

PLoS One. 2014 Mar 25;9(3):e92606. doi: 10.1371/journal.pone.0092606. eCollection 2014.

16.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

17.

Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis.

Lane D, Matte I, Laplante C, Garde-Granger P, Rancourt C, Piché A.

J Ovarian Res. 2013 Nov 23;6(1):82. doi: 10.1186/1757-2215-6-82.

18.

Human papillomavirus type 56 polymorphism in Canadian women with and without cervical lesions.

Rodrigues-Coutlée C, Archambault J, Money D, Ramanakumar AV, Raboud J, Hankins C, Koushik A, Richardson H, Brassard P, Franco EL, Coutlée F; Canadian Women's HIV Study Group.

J Clin Virol. 2013 Dec;58(4):660-5. doi: 10.1016/j.jcv.2013.10.015. Epub 2013 Oct 17.

PMID:
24210329
19.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

20.

Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis.

Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piché A.

Mol Cancer. 2012 Nov 17;11:84. doi: 10.1186/1476-4598-11-84.

Supplemental Content

Loading ...
Support Center